Learn More
(Updated May 2014. All changed text is cast in yellow highlight.) NHS Evidence has accredited the process used by the British HIV Association (BHIVA) to produce guidelines. Accreditation is valid for five years from July 2012 and is applicable to guidance produced using the processes described in the British HIV Association (BHIVA) Guideline Development(More)
BACKGROUND Initiating therapy with a low CD4 cell count is associated with a substantially greater risk of disease progression and death than earlier initiation. We examined factors associated with late presentation of HIV using the new European consensus definition (CD4 cell count <350 cells/mm3) and mortality. METHODS Patients newly diagnosed with HIV(More)
Coinfection with HIV adversely impacts every stage of hepatitis C (HCV) infection. Liver damage in HCV infection results from host antiviral responses rather than direct viral pathogenesis. Despite depressed cellular immunity, coinfected patients show accelerated hepatic fibrosis compared with HCV monoinfected patients. This paradox is poorly understood.(More)
INTRODUCTION Combination antiretroviral therapy (cART) may affect vitamin D [25(OH)D], parathyroid hormone (PTH), bone mineral density (BMD) and bone turnover (BT). Reduced BMD and secondary hyperparathyroidism have been reported with tenofovir (TDF). We investigated the associations between TDF and bone markers, especially in 25(OH)D-deficient patients. (More)
Purpose of study With combination antiretroviral therapy (cART), HIV-associated mortality rates have declined substantially in the UK. However HIV-infected adults are living longer to develop co-morbidities, including low bone mineral density (BMD). This study investigates fractures in a UK cohort of HIV-infected adults. Methods A cross-sectional survey of(More)
  • 1